Following publication of the Research Article by Oosten, Matic, van Schaik, Look, Jongen, Mathijssen & van der Rijt, titled ‘Opioid treatment failure in cancer patients: the role of clinical and genetic factors’, which appeared in the August 2016 issue of Pharmacogenomics (Pharmacogenomics [Lond.] 17[13], 1391–1403 [2016]; doi:10.2217/pgs-2016-0082), we have corrected the paragraph in the results section under heading ‘Association of treatment failure with clinical and genetic factors in univariate and multivariate analysis’, subheading ‘All patients’ has been corrected as follows:
In univariate analysis, factors associated with failure of treatment were age (odds ratio [OR]: 0.58; 95% CI: 0.39–30.97; p = 0.039), use of adjuvant pain medication started on T0 or later (OR: 3.04; 95% CI: 1.76–75.24; p = 0.000), use of corticosteroids started on T0 or later (OR: 1.95; 95% CI: 1.15–13.29; p = 0.012), pain at rest (category severe pain OR: 3.13; 95% CI: 1.29–27.56; p = 0.011) and worst pain at T0 (category severe pain OR: 3.21; 95% CI: 1.19–18.69; p = 0.022), the MEDD at T0 (Q3: OR: 2.27; 95% CI: 1.04–04.92; p = 0.038 and Q4: OR: 3.10; 95% CI: 1.45–46.63; p = 0.004) and the rs12948783 SNP in RHBDF2 (OR: 0.55; 95% CI: 0.32–30.96; p = 0.035). Of these, the use of adjuvant pain medication (OR: 3.49; p = 0.000), severe pain at rest (OR: 2.67; p = 0.048) and the rs12948783 SNP in RHBDF2 (OR: 0.37; p = 0.056) were (possibly) independent as shown in multivariable analysis (Tables 1–3). When the analysis was corrected for opioid dose, results were unchanged.
The authors and editors of Pharmacogenomics would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.